Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 10, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 15,000 shares were sold in multiple transactions at varying prices.
• The prices ranged from $115.51 to $120.13 per share.
• Following these transactions, Afeyan directly owns 2,269,015 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions executed under a pre-arranged plan.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan allows insiders to sell shares over a period of time while avoiding concerns about trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates